Vida Ventures Advisors’s Centessa Pharmaceuticals CNTA Stock Holding History

Vida Ventures Advisors’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-3,931,818	Closed	-$65.9M	–	4
2024 Q4	$65.9M	Hold	3,931,818	–	–	45.01%	1
2024 Q3	$62.9M	Hold	3,931,818	–	–	45.36%	1
2024 Q2	$35.5M	Hold	3,931,818	–	–	38.83%	1
2024 Q1	$44.4M	Hold	3,931,818	–	–	24.68%	2
2023 Q4	$31.3M	Hold	3,931,818	–	–	37.26%	1
2023 Q3	$25.4M	Hold	3,931,818	–	–	39.38%	1
2023 Q2	$24.3M	Hold	3,931,818	–	–	31.78%	2
2023 Q1	$15.1M	Hold	3,931,818	–	–	20.71%	2
2022 Q4	$12.2M	Hold	3,931,818	–	–	16.38%	3
2022 Q3	$15.8M	Hold	3,931,818	–	–	14.18%	4
2022 Q2	$19.1M	Hold	3,931,818	–	–	16.18%	4
2022 Q1	$35.3M	Hold	3,931,818	–	–	20.51%	1
2021 Q4	$44.3M	Hold	3,931,818	–	–	16.56%	3
2021 Q3	$65.7M	Hold	3,931,818	–	–	18.81%	1
2021 Q2	$87.3M	Buy	+3,931,818	New	+$92.4M	21.9%	1

Other funds holding CNTA

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

IVLAV

Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return

General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vida Ventures Advisors's CNTA Position: Q1 2025 in Review

Vida Ventures Advisors sold out of Centessa Pharmaceuticals (CNTA) in Q1 2025, closing a stake of 3,931,818 shares — an estimated $65.9M sold.

Vida Ventures Advisors first reported a position in CNTA in Q2 2021 and held it in 15 quarters. The position peaked at $87.3M in Q2 2021. 129 funds tracked by Wall St. Rank hold CNTA as of Q1 2025.

Vida Ventures Advisors reported no remaining Centessa Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Vida Ventures Advisors sold 3,931,818 Centessa Pharmaceuticals shares in Q1 2025, an estimated $65.9M.
Vida Ventures Advisors first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 15 quarters.
Vida Ventures Advisors's Centessa Pharmaceuticals position peaked at $87.3M in Q2 2021.
129 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2025.

Based on Vida Ventures Advisors's 13F filing for Q1 2025, filed 3 Apr 2025.